Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

The biological and functional heterogeneity between tumors—both across and within cancer
types—poses a challenge for immunotherapy. To understand the factors underlying tumor …

The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Most tumors are unresponsive to immune checkpoint blockade, especially if deep
immunosuppression in the tumor develops prior to and prevents T cell immunosurveillance …

Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has
ushered in a new era of anti-tumor therapy, with sustained responses and significant …

Type 1 conventional dendritic cells (cDC1s) are typically thought to be dysregulated
secondarily to invasive cancer. Here, we report that cDC1 dysfunction instead develops in …